Uveitis Global Clinical Trials Review Report 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status

The report on Uveitis clinical trials highlights opportunities in understanding trial count, enrollment trends, and successful trial regions. It aids strategic investment decisions by identifying key ...
Le Lézard

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Pfizer Inc. today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
Mirage News

Pfizer's BRAFTOVI Boosts Response in Metastatic CRC

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Pharmabiz

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John

Single-cell research of patients’ immune cells to guide future treatments: Dr Arivusudar John: Shardul Nautiyal, Mumbai Friday, January 16, 2026, 08:00 Hrs [IST] Single-Cell Ana ...
Pulse Today

Investigating diarrhoea – a rational approach to testing in primary care

Gastroenterology specialists Dr Andy Li and Dr Jessica Gurung outline a rational approach to investigating recurrent ...

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...
The Malaysian Reserve

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...